Dianthus Therapeutics stock analysis
Dianthus Therapeutics (87E) Stock Price & Analysis
87E Stock Chart & Stats
- Day’s Range
- EUR 77.50 - EUR 78.50
- 52-Week Range
- EUR 30.60 - EUR 99.50
- Previous Close
- EUR 78.50
- Volume
- N/A
- Average Volume (3M)
- 63
- Market Cap
- EUR 4.36B
- Enterprise Value
- EUR 4.21B
- Total Cash (Recent Filing)
- EUR 837.78M
- Total Debt (Recent Filing)
- EUR 1.21M
- Price to Earnings (P/E)
- 2827.7
- Beta
- 0.13
- Next Earnings
- Mar 16, 2027 (Est.)
- EPS Estimate
- -0.87
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Very Low Leverage
Extremely low leverage limits financial risk from borrowing and preserves flexibility for research, development, and other corporate needs. The sizable equity base gives Dianthus more capacity to fund its clinical-stage strategy without the added pressure of substantial debt service.
Focused Therapeutic Strategy
A focused antibody strategy around Complement Factor C1s provides a clear scientific direction rather than a highly dispersed development portfolio. Targeting severe autoimmune and inflammatory diseases could support meaningful clinical value if development successfully demonstrates efficacy and safety.
Expanded Capital Base
Substantial growth in equity and assets strengthens the company’s financial foundation for a clinical-stage biotechnology model. This larger capital base can support continued development activity and provides more flexibility than a similarly positioned company with a smaller funding cushion.
Bears Say
No Commercial Revenue
Without marketed products, the company lacks a recurring commercial revenue stream to fund operations or validate its business model through customer demand. Financial progress therefore remains dependent on clinical development and future financing or partnering outcomes.
Persistent Cash Burn
Heavy negative operating and free cash flow indicates that ongoing research and corporate activities consume substantial cash. If this burn persists, Dianthus will need continued access to funding, which can constrain strategic flexibility and increase dependence on external capital.
Development-Stage Losses
The company remains far from breakeven because development spending materially exceeds its small and volatile revenue base. Continued net losses leave profitability dependent on successful clinical progress, future commercialization, and the eventual scale-up of operating revenue.
Dianthus Therapeutics News
87E FAQ
What was Dianthus Therapeutics’s price range in the past 12 months?
What is Dianthus Therapeutics’s market cap?
When is Dianthus Therapeutics’s upcoming earnings report date?
How were Dianthus Therapeutics’s earnings last quarter?
Is Dianthus Therapeutics overvalued?
Does Dianthus Therapeutics pay dividends?
What is Dianthus Therapeutics’s EPS estimate?
How many shares outstanding does Dianthus Therapeutics have?
What happened to Dianthus Therapeutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Dianthus Therapeutics?
What is the TipRanks Smart Score and how is it calculated?
Dianthus Therapeutics Stock Smart Score
Company Description
Dianthus Therapeutics
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Marino Garcia
- Employees
- 92
- Website
- dianthustx.com
- Address
- 7 Times Square, New York, NY, 10036, US
Dianthus Therapeutics (87E) Earnings & Revenues
87E Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 8 | 6 | 8 |
| Technical Analysis | 2 | 6 | 2 |
| Moving Averages | 6 | 0 | 6 |













